DE3871596T3 - Anwendung eines Prostaglandins in Mischung mit einem adrenergischen Blocker zur Verminderung des Augen-Innendruckes. - Google Patents

Anwendung eines Prostaglandins in Mischung mit einem adrenergischen Blocker zur Verminderung des Augen-Innendruckes.

Info

Publication number
DE3871596T3
DE3871596T3 DE3871596T DE3871596T DE3871596T3 DE 3871596 T3 DE3871596 T3 DE 3871596T3 DE 3871596 T DE3871596 T DE 3871596T DE 3871596 T DE3871596 T DE 3871596T DE 3871596 T3 DE3871596 T3 DE 3871596T3
Authority
DE
Germany
Prior art keywords
prostaglandin
adrenergic
blocker
mixture
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3871596T
Other languages
German (de)
English (en)
Other versions
DE3871596T2 (de
DE3871596D1 (de
Inventor
Laszlo Z Bito
Johan Wilhelm Stjernschantz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University in the City of New York
Original Assignee
Pharmacia and Upjohn AB
Columbia University in the City of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21876714&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3871596(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia and Upjohn AB, Columbia University in the City of New York filed Critical Pharmacia and Upjohn AB
Application granted granted Critical
Publication of DE3871596D1 publication Critical patent/DE3871596D1/de
Publication of DE3871596T2 publication Critical patent/DE3871596T2/de
Publication of DE3871596T3 publication Critical patent/DE3871596T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE3871596T 1987-04-03 1988-03-28 Anwendung eines Prostaglandins in Mischung mit einem adrenergischen Blocker zur Verminderung des Augen-Innendruckes. Expired - Lifetime DE3871596T3 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3448487A 1987-04-03 1987-04-03

Publications (3)

Publication Number Publication Date
DE3871596D1 DE3871596D1 (de) 1992-07-09
DE3871596T2 DE3871596T2 (de) 1993-01-21
DE3871596T3 true DE3871596T3 (de) 2000-09-07

Family

ID=21876714

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3871596T Expired - Lifetime DE3871596T3 (de) 1987-04-03 1988-03-28 Anwendung eines Prostaglandins in Mischung mit einem adrenergischen Blocker zur Verminderung des Augen-Innendruckes.

Country Status (9)

Country Link
EP (1) EP0286903B2 (cg-RX-API-DMAC7.html)
JP (1) JP2726672B2 (cg-RX-API-DMAC7.html)
AT (1) ATE76750T1 (cg-RX-API-DMAC7.html)
AU (1) AU607981B2 (cg-RX-API-DMAC7.html)
CA (1) CA1314220C (cg-RX-API-DMAC7.html)
DE (1) DE3871596T3 (cg-RX-API-DMAC7.html)
ES (1) ES2042625T5 (cg-RX-API-DMAC7.html)
GR (2) GR3004794T3 (cg-RX-API-DMAC7.html)
HU (1) HU211835A9 (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1334168C (en) * 1988-04-26 1995-01-31 Louis M. De Santis Antiglaucoma compositions containing combinations of .alpha.-2 agonists and .beta. blockers
US5173507A (en) * 1988-07-18 1992-12-22 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
CA2021316C (en) * 1989-07-27 2000-10-24 Ming Fai Chan Intraocular pressure reducing 11-acyl prostaglandins
US5028624A (en) * 1989-07-27 1991-07-02 Allergan, Inc. Intraocular pressure reducing 9,15-diacyl prostaglandins
US4994274A (en) * 1989-07-27 1991-02-19 Allergan, Inc. Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using
US5055467A (en) * 1989-11-13 1991-10-08 Allergan, Inc. Pharmaceutical epinephrine-pilocarpine compounds
US5198545A (en) * 1989-11-13 1993-03-30 Allergan, Inc. Pharmaceutical epinephrine-pilocarpine compounds and process of preparation thereof
US5011856A (en) * 1990-03-12 1991-04-30 Allergan, Inc. Use of prostaglandin F3 α as an ocular hypotensive agent
ES2059058T3 (es) * 1990-05-22 1994-11-01 R Tech Ueno Ltd Combinacion sinergica para uso oftalmico.
EP0458590B1 (en) * 1990-05-22 1996-01-10 R-Tech Ueno Ltd. Treatment of ocular hypertention with a synergistic combination
ES2069823T3 (es) * 1990-05-22 1995-05-16 R Tech Ueno Ltd Tratamiento de la hipertension ocular con una combinacion sinergica ocular.
US5238961A (en) * 1990-06-14 1993-08-24 Allergan, Inc. Pgf 1-alcohols and their use as ocular hypotensives
TW210287B (cg-RX-API-DMAC7.html) * 1991-03-01 1993-08-01 Kabushikaisha Ueno Seiyaku Oyo Kenkyujo
PT561073E (pt) * 1992-03-19 2002-04-29 R Tech Ueno Ltd Tratamento da hipertensao ocular com beta-bloqueadores e derivados de acido prostanoico
JPH06107547A (ja) * 1992-10-01 1994-04-19 Aarutetsuku Ueno:Kk 眼科用組成物
ES2105333T3 (es) * 1992-10-13 1997-10-16 Alcon Lab Inc Combinaciones de prostaglandinas y derivados de clonidina para el tratamiento del glaucoma.
US5574066A (en) * 1992-10-28 1996-11-12 Allergan Intraocular pressure reducing 15-acyl prostaglandins
SE9402816D0 (sv) * 1994-08-24 1994-08-24 Pharmacia Ab Method and meams for drug administration
US5698733A (en) * 1994-09-30 1997-12-16 Alcon Laboratories, Inc. Use of 9-deoxy prostaglandin derivatives to treat glaucoma
AU746893B2 (en) * 1998-01-23 2002-05-02 Merck Sharp & Dohme B.V. Method for increasing oxygen tension in the optic nerve and retina
CN1259051C (zh) * 2001-04-19 2006-06-14 帝化制药株式会社 药物及药物试剂盒
TWI298257B (en) 2001-05-31 2008-07-01 Allergan Inc Hypotensive lipid and timolol compositions and methods of using same
AU2007200821A1 (en) * 2001-05-31 2007-03-15 Allergan, Inc. Hypotensive lipid and timolol compositions and methods of using same
TW200305424A (en) 2002-01-29 2003-11-01 Santen Pharmaceutical Co Ltd Glaucoma-treating agent comprising bunazosin and prostaglandin
EP1541151B1 (en) * 2002-08-29 2012-02-22 Santen Pharmaceutical Co., Ltd. REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDINS
KR101223886B1 (ko) * 2002-11-18 2013-01-17 산텐 세이야꾸 가부시키가이샤 Ｒｈｏ 키나아제 억제제와 β 차단약으로 이루어진 녹내장 치료제
US7186744B2 (en) * 2003-11-13 2007-03-06 Allergan, Inc. Prostamides for the treatment of glaucoma and related diseases
ES2416334T3 (es) 2005-07-12 2013-07-31 Kowa Company. Ltd. Agente para la prevención o el tratamiento del glaucoma
EP2127638A1 (en) * 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
WO2011034192A1 (ja) * 2009-09-17 2011-03-24 千寿製薬株式会社 ラタノプロストを含有する水性点眼剤、並びにラタノプロストの樹脂への吸着の抑制方法
EP2598118B1 (en) 2010-07-29 2018-09-05 Allergan, Inc. Preservative free bimatoprost and timolol solutions
US9061034B2 (en) 2010-07-29 2015-06-23 Allergan, Inc. Preservative free bimatoprost and timolol solutions
EP2671586B1 (en) 2011-02-04 2018-05-30 Kowa Co., Ltd. Drug therapy for preventing or treating glaucoma
CA3099517C (en) * 2012-07-13 2022-04-26 Santen Pharmaceutical Co., Ltd. Combinations comprising a sulfonamide compound for the treatment of glaucoma or ocular hypertension
WO2018033854A1 (en) 2016-08-15 2018-02-22 Santen Pharmaceutical Co., Ltd. Ophthalmic composition and a method for treating ocular hypertension and glaucoma
KR20200103041A (ko) 2017-12-21 2020-09-01 산텐 세이야꾸 가부시키가이샤 오미데네팍의 조합
ES2972934T3 (es) 2017-12-21 2024-06-17 Santen Pharmaceutical Co Ltd Combinación de sepetaprost y ripasudil para su uso en la profilaxis o tratamiento del glaucoma o hipertensión ocular

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4454154A (en) * 1981-06-23 1984-06-12 American Hospital Supply Corporation Method for treating glaucoma by the topical administration of selectively metabolized beta-blocking agents
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
DE3300933A1 (de) * 1983-01-13 1984-07-19 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von d,l- und d-carazolol als antiglaukommittel sowie arzneimittel, die diese stoffe enthalten
DE3785602T2 (de) * 1986-03-13 1993-09-02 Univ Columbia Verwendung von a-, b- und c-prostaglandinen und deren derivaten zur behandlung von augen-hypertension und glaukom.

Also Published As

Publication number Publication date
GR3004794T3 (cg-RX-API-DMAC7.html) 1993-04-28
HU211835A9 (en) 1995-12-28
JP2726672B2 (ja) 1998-03-11
JPS63313728A (ja) 1988-12-21
ATE76750T1 (de) 1992-06-15
CA1314220C (en) 1993-03-09
AU607981B2 (en) 1991-03-21
DE3871596T2 (de) 1993-01-21
EP0286903B2 (en) 2000-03-29
DE3871596D1 (de) 1992-07-09
EP0286903A1 (en) 1988-10-19
GR3033721T3 (en) 2000-10-31
ES2042625T3 (es) 1993-12-16
ES2042625T5 (es) 2000-07-16
AU1387088A (en) 1988-10-06
EP0286903B1 (en) 1992-06-03

Similar Documents

Publication Publication Date Title
DE3871596T3 (de) Anwendung eines Prostaglandins in Mischung mit einem adrenergischen Blocker zur Verminderung des Augen-Innendruckes.
US4952581A (en) Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure
DE68929435T2 (de) Prostaglandinderivate zur Behandlung des grünen Stars oder einer okularen Hypertension
DE68913650T2 (de) Antiglaukoma-zubereitungen, die kombinationen von alpha-2 agonisten und beta-blocker enthalten.
DE3785602T2 (de) Verwendung von a-, b- und c-prostaglandinen und deren derivaten zur behandlung von augen-hypertension und glaukom.
DE69634414T2 (de) Verwendung von substituierten isochinolinsulfonyl-verbindungen zur herstellung eines medikaments für die behandlung von glaukom und okularer ischämie
DE69530594T2 (de) Verfahren und mittel zur arzneistoffverabreichung
DE69524446T2 (de) Ep2-rezeptoragonisten als mittel zur senkung des augeninnendrucks
DE3872701T2 (de) Prostaglandin-derivate zur behandlung von glaucoma oder augenueberdruck.
US6037368A (en) 8-iso- prostaglandins for glaucoma therapy
Lee et al. Pharmacological testing in the laser-induced monkey glaucoma model
DE69534620T2 (de) Verfahren zur behandlung von augenerkrankungen
DE3317692A1 (de) Verwendung von metkephamid oder eines pharmazeutisch unbedenklichen salzes hiervon als analgetikum bei traechtigen weiblichen tieren und insbesondere bei schwangeren frauen
DE3850778T2 (de) Verwendung von tetracycline zur herstellung eines arzneimittels zum herabsetzen des augendrucks.
DE60008151T2 (de) 5-ht2 agonisten als mittel zur kontrolle des augeninnendrucks und zur behandlung von glaukom
DE69834638T2 (de) Zusammensetzung zur Behandlung von Augenhypertension oder Glaukom
EP0585896B1 (de) Arzneimittel zur topischen Anwendung am Auge zur Behandlung des erhöhten intraokularen Drucks
DE69028877T2 (de) Verwendung von Phenylethanolaminen zur Herstellung von Medikamenten gegen Augenleiden
DE3873234T2 (de) Zusammensetzung fuer die lokale behandlung von glaukom oder augen-hypertonie.
Crawford et al. Dose-related effects of prostaglandin F2 alpha isopropylester on intraocular pressure, refraction, and pupil diameter in monkeys.
Leopold et al. Observations on the pharmacology of glaucoma
DE69417584T2 (de) 7-[carboxyalkyl oder alkenyl]-6-[alkyl oder alkenyl] 3-oxo-2,4-dioxobicyclo-[3.2.1]octan und dessen derivate
DE68919649T2 (de) Kombinationen von sympathomimetika mit beta-1 selektiven betablockern enthaltende mittel gegen glaucoma.
Podos et al. Pharmacologic alteration of aqueous humor dynamics in normotensive and glaucomatous monkey eyes
CA2052438A1 (en) Method to reduce intraocular pressure without causing miosis

Legal Events

Date Code Title Description
8380 Miscellaneous part iii

Free format text: DIE PATENTINHABER LAUTEN RICHTIG: KABI PHARMACIA AB, UPPSALA, SE PHARMACIA AB,UPPSALA, SE

8363 Opposition against the patent
8328 Change in the person/name/address of the agent

Free format text: DERZEIT KEIN VERTRETER BESTELLT

8327 Change in the person/name/address of the patent owner

Owner name: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF

8366 Restricted maintained after opposition proceedings